# Alnylam Pharmaceuticals (ALNY) — News

ALNY · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/alny/news

## Recent headlines

- [Alzheimer stocks rose in after-hours trading, with Anavex Life Sciences up 2.9%, while Alnylam Pharmaceuticals and BioMarin Pharmaceutical gained.](https://www.ainvest.com/news/alzheimer-stocks-rose-hours-trading-anavex-life-sciences-2-9-alnylam-pharmaceuticals-biomarin-pharmaceutical-gained-2610-45) — AInvest Wire, Oct 15, 2026
  Alzheimer's disease-related stocks saw gains in after-hours trading on October 15, 2026. Anavex Life Sciences (Nasdaq: AVXL) rose 2.9%, reflecting investor optimism about its pipeline of therapies targeting neurodegenerative conditions. Alnylam Pharmaceuticals (Nasdaq: ALNY) and BioMarin…
- [Alnylam Pharmaceuticals, Inc.: Jefferies cuts target price to $250 from $260](https://www.ainvest.com/news/alnylam-pharmaceuticals-jefferies-cuts-target-price-250-260-2610) — AInvest Wire, Oct 15, 2026
  Jefferies has revised its target price for Alnylam Pharmaceuticals, Inc. (ALNY) to $250 from $260, reflecting a 3.8% reduction in its price forecast for the biotech firm. The adjustment comes amid ongoing market evaluation of Alnylam’s RNA interference therapies and recent share price volatility.…
- [Alnylam Pharmaceuticals, Inc.: Citigroup cuts target price to $320 from $340](https://www.ainvest.com/news/alnylam-pharmaceuticals-citigroup-cuts-target-price-320-340-2610) — AInvest Wire, Oct 14, 2026
  Citigroup has revised its price target for Alnylam Pharmaceuticals, Inc. (ALNY), lowering it to $320 from $340, reflecting a shift in analyst sentiment amid recent market performance and financial developments. The adjustment comes as the stock has experienced a 9% decline over the past seven days…
- [Alnylam Pharmaceuticals, Inc.: RBC cuts target price to $345 from $350](https://www.ainvest.com/news/alnylam-pharmaceuticals-rbc-cuts-target-price-345-350-2610) — AInvest Wire, Oct 8, 2026
- [Adarx Pharma said to guide IPO pricing to top of range or above](https://www.ainvest.com/news/adarx-pharma-guide-ipo-pricing-top-range-2609) — AInvest Wire, Sep 24, 2026
  ADARx Pharmaceuticals is expected to price its upcoming Nasdaq IPO at or above the top of its $15–$17 per share range, according to recent market signals and investor sentiment. The company is offering 21.875 million shares in the offering, which could raise up to $350 million and value the firm at…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).